Απόσυρση φαρμάκου

[orfeo]

April 9, 2009 — Efalizumab (Raptiva, Genentech, Inc) is undergoing a voluntary, phased withdrawal in US markets because of a potential risk to patients of developing progressive multifocal leukoencephalopathy (PML). Efalizumab is used for the treatment of chronic moderate to severe plaque psoriasis.
....................................
Efalizumab is an anti-CD11a antibody immunosuppressant drug. PML is a rapidly progressive infection of the central nervous system caused by the John Cunningham (JC) virus that leads to death or severe disability. It is currently not possible to identify patients at increased risk for PML before or during efalizumab therapy, and there is no known treatment for PML.

Δεν είναι ορατοί οι σύνδεσμοι (links). Εγγραφή ή Είσοδος

[EzeΤΡΟΛ]

Άραγε, αφορά και τις άλλες "Ουμάμπες";